Navigation Links
Marshall Edwards Announces Publication of Phase II Clinical Trial Results Highlighting Activity of Intravenous Phenoxodiol
Date:3/21/2011

ients in multiple clinical trials via oral or intravenous routes and has been well tolerated. Marshall Edwards has identified a next-generation compound called NV-143 that in laboratory studies has demonstrated significantly more activity than Phenoxodiol against a broad range of tumor cell lines. In addition to being more active as a single agent, NV-143 appears to be superior in its ability to synergize with platinum-based chemotherapy in pre-clinical studies. As a result, the Company plans to initiate a Phase I clinical trial of intravenous NV-143 later this year, followed immediately thereafter by randomized Phase II trials in combination with chemotherapy.

"These published results combined with data from previous studies reinforce our conclusion that intravenous administration is the optimal route of delivery for this class of drugs and give us added confidence moving forward as we develop our next-generation compound NV-143 for the clinic," said Robert D. Mass, MD, Acting Chief Medical Officer of Marshall Edwards.

About Marshall Edwards

Marshall Edwards, Inc. (Nasdaq: MSHL) is a San Diego-based oncology company focused on the clinical development of novel anti-cancer therapeutics. The Company's lead programs focus on two families of small molecules that result in the inhibition of tumor cell metabolism. The first and most advanced is a NADH oxidase inhibitor program that includes lead drug candidate NV-143. The second is a mitochondrial inhibitor program that includes NV-128 and its next-generation candidate NV-344. Both programs are expected to advance into the clinic in 2011. For more information, please visit www.marshalledwardsinc.com.

Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical trials and approved by the FDA as being safe and effective for the i
'/>"/>

SOURCE Marshall Edwards, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Marshall Edwards Receives Positive Response From NASDAQ
2. Marshall Edwards to Host Annual Meeting of Stockholders
3. Marshall Edwards Receives NASDAQ Notice Of Non-Compliance; Intends To Request Hearing
4. Marshall Edwards Announces Presentation of New Data Showing Activity in Chemotherapy-Resistant Ovarian Cancer Cells
5. Edwards Lifesciences Announces First Implants in U.S. Study of Minimally-Invasive Pulmonic Valve
6. Edwards Resilient Trial Demonstrates Statistically Superior Results for Treating Peripheral Arterial Disease in the Leg
7. Quest Diagnostics Incorporated Announces Proposed Senior Notes Offering
8. CCS Medical Announces New President and Chief Executive Officer
9. Echo Therapeutics Announces 2010 Financial Results
10. NeuroFocus Announces Worlds First Wireless Full-Brain EEG Measurement Headset: Mynd™
11. ViroPharma Announces Positive CHMP Opinion for Cinryze® (C1 Inhibitor [Human]) in European Union
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , FARUM, Denmark and ... On July 31, 2015 the US Food and Drug Administration ... of Major Depressive Disorder in adult patients who have failed ... current episode. TMS is a non-invasive technique for stimulating neural ... suffering from Major Depressive Disorder. The procedure has been proven ...
(Date:8/28/2015)... Massachusetts y LONDRES, 28 de agosto ... AEX: PHIA) anunció hoy su participación en el  ... exhibirá sus soluciones cardiológicas más recientes y novedosas, ... Cardiovascular, que conectan a las personas y la ... de ayudar a diagnosticar, guiar los tratamientos y ...
(Date:8/27/2015)... FRANKLIN, Mass. , Aug. 27, 2015 /PRNewswire/ ... in the KSSTA Knee Journal, compared the Arthrosurface ... "inlay" Arthroplasty design, versus an "onlay" design implant ... showed similar improvements in function and pain scores, ... showed progression of osteoarthritis (OA). However, 53% of ...
Breaking Medicine Technology:Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 2Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 2Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 4Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 5Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 2Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 3
... Sept. 30 /PRNewswire-Asia/ -- Winner Medical Group Inc. ... leading manufacturer of medical dressings, medical disposables and ... products industries in China, today announced that it ... store at www.purcotton.com . Opening ...
... Announces Fourth Quarter and Fiscal Year 2010 Results -- LAIYANG, China, Sept. 30 /PRNewswire-Asia-FirstCall/ -- ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are keyed ...
Cached Medicine Technology:Winner Medical Launches Its Own PurCotton® B2C Website 2Winner Medical Launches Its Own PurCotton® B2C Website 3Jiangbo Pharmaceuticals Announces Fourth Quarter and Fiscal Year 2010 Results 2Jiangbo Pharmaceuticals Announces Fourth Quarter and Fiscal Year 2010 Results 3Jiangbo Pharmaceuticals Announces Fourth Quarter and Fiscal Year 2010 Results 4Jiangbo Pharmaceuticals Announces Fourth Quarter and Fiscal Year 2010 Results 5Jiangbo Pharmaceuticals Announces Fourth Quarter and Fiscal Year 2010 Results 6Jiangbo Pharmaceuticals Announces Fourth Quarter and Fiscal Year 2010 Results 7Jiangbo Pharmaceuticals Announces Fourth Quarter and Fiscal Year 2010 Results 8Jiangbo Pharmaceuticals Announces Fourth Quarter and Fiscal Year 2010 Results 9Jiangbo Pharmaceuticals Announces Fourth Quarter and Fiscal Year 2010 Results 10Jiangbo Pharmaceuticals Announces Fourth Quarter and Fiscal Year 2010 Results 11Jiangbo Pharmaceuticals Announces Fourth Quarter and Fiscal Year 2010 Results 12Jiangbo Pharmaceuticals Announces Fourth Quarter and Fiscal Year 2010 Results 13Jiangbo Pharmaceuticals Announces Fourth Quarter and Fiscal Year 2010 Results 14Jiangbo Pharmaceuticals Announces Fourth Quarter and Fiscal Year 2010 Results 15Jiangbo Pharmaceuticals Announces Fourth Quarter and Fiscal Year 2010 Results 16Jiangbo Pharmaceuticals Announces Fourth Quarter and Fiscal Year 2010 Results 17Jiangbo Pharmaceuticals Announces Fourth Quarter and Fiscal Year 2010 Results 18
(Date:8/30/2015)... (PRWEB) , ... August 30, 2015 , ... ... Ultrasound (HIFU) medical devices for the treatment of prostate cancer, has announced the ... this summer at the treatment center in Puerto Vallarta, Mexico. , The Sonablate® ...
(Date:8/29/2015)... ... 29, 2015 , ... "I have been a licensed physical ... specialize in manual therapy, and my invention will provide headache sufferers a solution ... muscle dysfunction throughout the body." , They developed THE RELIEVER to alleviates headaches, ...
(Date:8/29/2015)... ... August 29, 2015 , ... Next weekend is Labor ... (which astronomically, officially ends on September 22nd this year). For IT security personnel, it ... linger on which could prove far more costly than a simple headache. , Joe ...
(Date:8/29/2015)... ... August 29, 2015 , ... ... freely market and sell Arterosil and Arterosil HP, and that all claims and ... sued Vascular Health Sciences, LLC (VHS) in the United States District Court for ...
(Date:8/28/2015)... ... August 28, 2015 , ... The Kentucky State Department of ... for the position they are applying for, they are unable to pass the initial ... considering altering drug testing policies in order to be able to hire long-term, skilled ...
Breaking Medicine News(10 mins):Health News:Image Fusion Technology Combines MRI and Ultrasound Images to Treat Prostate Cancer 2Health News:Inventors and InventHelp Clients Develops Tension Reliever (LGI-1951) 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 3Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 4Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 2Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 3Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 4
... taking common antibacterial medication , THURSDAY, July 2 (HealthDay ... can cause sensorineural hearing loss, finds a new study. ... fibrosis patients treated over a 13-year period at Children,s ... them suffered from sensorineural hearing loss. Of those seven ...
... 2 Cardinal Health today announced that Bruce L. Downey ... completion of the planned spinoff of CareFusion Corporation, replacing John ... reasons after 22 years of service to the company as ... former chairman and chief executive officer of Barr Pharmaceuticals, Inc. ...
... ... contest for the best new industry application of its hand-centric motion capture and ... offers the most sophisticated hand-centric motion capture solutions in the marketplace. The winner ... free use for 12 months to develop their winning industry-application concept! , ...
... ,Help is Here Express, bus tour will be stopping in ... at various cities in order to help uninsured and ... medicines for free or nearly free. With the state,s unemployment ... year ago, the Partnership for Prescription Assistance (PPA) is ready ...
... , This release is available in Spanish ... of this kind of humour) favour the mental mechanisms which ... macho attitudes. Those are the conclusions of a study carried ... be released tomorrow Thursday 2nd of July in the framework ...
... SETO Holdings, Inc. (Pink Sheets: SETO) is pleased ... Virginia at 1244 Sycamore Sq. (Shopping Center), Midlothian (Richmond, VA). ... can go to ADVANCED,s web site (877allears.com) or contact Richard ... , , Forward-Looking Statements: Statements in this new ...
Cached Medicine News:Health News:Cardinal Health Appoints Bruce Downey to Board of Directors; John McCoy Retires From Board After 22 Years 2Health News:CyberGlove Systems Hosts Worldwide Contest for New Motion Capture Technology Applications 2Health News:CyberGlove Systems Hosts Worldwide Contest for New Motion Capture Technology Applications 3Health News:Partnership for Prescription Assistance Prepared to Help North Dakota Workers Hurt by Recession 2Health News:Partnership for Prescription Assistance Prepared to Help North Dakota Workers Hurt by Recession 3Health News:Partnership for Prescription Assistance Prepared to Help North Dakota Workers Hurt by Recession 4Health News:Sexist jokes favor the mental mechanisms that justify violence against women 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: